AR099909A1 - ANTI-OX40 ANTIBODIES AND METHODS OF USE - Google Patents
ANTI-OX40 ANTIBODIES AND METHODS OF USEInfo
- Publication number
- AR099909A1 AR099909A1 ARP150100976A ARP150100976A AR099909A1 AR 099909 A1 AR099909 A1 AR 099909A1 AR P150100976 A ARP150100976 A AR P150100976A AR P150100976 A ARP150100976 A AR P150100976A AR 099909 A1 AR099909 A1 AR 099909A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- hvr
- seq
- amino acid
- acid sequence
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un anticuerpo agonista de OX40 antihumano, caracterizado porque el anticuerpo agota células que expresan OX40 humano in vitro y se une con OX40 humano con una afinidad de menos o igual a aproximadamente 1 nM. Reivindicación 29: El anticuerpo de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque el anticuerpo comprende (a) un dominio de VH que comprende (i) HVR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 2, 8 o 9, (ii) HVR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 3, 10, 11, 12, 13 ó 14 y (iii) HVR-H3 que comprende una secuencia de aminoácidos seleccionados de SEQ ID Nº 4, 15 ó 19; y (iv) HVR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 5, (v) HVR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 6 y (vi) HVR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 7, 22, 23, 24, 25, 26, 27 ó 28. Reivindicación 59: Ácido nucleico aislado caracterizado porque codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones precedentes. Reivindicación 61: Un método de producción de un anticuerpo caracterizado porque comprende el cultivo de la célula huésped de acuerdo con la reivindicación 60 de modo de producir el anticuerpo. Reivindicación 69: Uso del anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 - 58 en la preparación de un medicamento caracterizado porque es para el tratamiento del cáncer.Claim 1: An anti-human OX40 agonist antibody, characterized in that the antibody depletes cells expressing human OX40 in vitro and binds with human OX40 with an affinity of less than or equal to about 1 nM. Claim 29: The antibody according to any of the preceding claims, characterized in that the antibody comprises (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID No. 2, 8 or 9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID No. 3, 10, 11, 12, 13 or 14 and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID No. 4, 15 or 19 ; and (iv) HVR-L1 comprising the amino acid sequence of SEQ ID No. 5, (v) HVR-L2 comprising the amino acid sequence of SEQ ID No. 6 and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID No. 7, 22, 23, 24, 25, 26, 27 or 28. Claim 59: Isolated nucleic acid characterized in that it encodes the antibody according to any of the preceding claims. Claim 61: A method of producing an antibody characterized in that it comprises culturing the host cell according to claim 60 so as to produce the antibody. Claim 69: Use of the antibody according to any of claims 1-58 in the preparation of a medicament characterized in that it is for the treatment of cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973193P | 2014-03-31 | 2014-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099909A1 true AR099909A1 (en) | 2016-08-24 |
Family
ID=58698535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100976A AR099909A1 (en) | 2014-03-31 | 2015-03-31 | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099909A1 (en) |
| MA (1) | MA39355B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112513088A (en) * | 2018-09-26 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | anti-OX 40 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| CN114685658A (en) * | 2020-12-30 | 2022-07-01 | 百力司康生物医药(杭州)有限公司 | OX40 targeted antibody and preparation method and application thereof |
-
2015
- 2015-03-30 MA MA39355A patent/MA39355B2/en unknown
- 2015-03-31 AR ARP150100976A patent/AR099909A1/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112513088A (en) * | 2018-09-26 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | anti-OX 40 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| CN112513088B (en) * | 2018-09-26 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | anti-OX 40 antibodies, antigen binding fragments thereof, and medical uses thereof |
| CN114685658A (en) * | 2020-12-30 | 2022-07-01 | 百力司康生物医药(杭州)有限公司 | OX40 targeted antibody and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| MA39355A1 (en) | 2018-12-31 |
| MA39355B2 (en) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161571A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| PE20150025A1 (en) | ANTIBODIES AND IMMUNOCONJUGATES AGAINST LY6E AND METHODS OF USE | |
| AR105026A1 (en) | ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE | |
| ES2685424T3 (en) | Anti-Jagged1 antibodies and procedures for use | |
| PE20141562A1 (en) | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE | |
| RU2017119543A (en) | ANTI-TIM3 ANTIBODIES AND WAYS OF THEIR APPLICATION | |
| PE20181336A1 (en) | ANTIBODIES THAT BIND INTERLEUKIN 8 (IL-8) AND ITS USES | |
| PE20170953A1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| AR091701A1 (en) | ANTI-CD22 ANTIBODIES AND IMMUNOCATE PLAYERS | |
| PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
| AR096687A1 (en) | ANTI-FCRH5 ANTIBODIES | |
| PE20181090A1 (en) | IMMUNE MODULATION AND TREATMENT OF SOLID TUMORS WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 | |
| PE20231958A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
| PE20170935A1 (en) | ANTI-HER2 AND IMMUNOCONJUGATED ANTIBODIES | |
| AR087405A1 (en) | METHODS TO TREAT CANCER BY THE USE OF ANTAGONISTS OF UNION TO THE AXIS PD-1 AND INHIBITORS OF MEK | |
| AR107077A1 (en) | ANTI-C5 ANTIBODIES AND METHODS FOR USE | |
| PE20191135A1 (en) | ANTITAU ANTIBODIES AND METHODS OF USE | |
| PE20142242A1 (en) | ANTI-CD27 HUMAN ANTIBODIES, METHODS, AND USES | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| AR085383A1 (en) | ANTIBODIES AGAINST HUMAN IL33R AND USES OF THE SAME | |
| AR091702A1 (en) | ANTI-CD79B ANTIBODIES AND IMMUNOCATE PLAYERS | |
| AR091462A1 (en) | ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE | |
| PE20120553A1 (en) | ANTI-FGFR3 ANTIBODIES | |
| RU2013143358A (en) | ANTI-FGFR4 ANTIBODIES AND WAYS OF THEIR APPLICATION | |
| AR102594A1 (en) | ANTI-IL-1b ANTIBODIES AND METHODS OF USE |